摘要
目的药物纳米晶体制备中的稳定剂筛选是十分复杂且耗时的过程。为了缩短耗时、减少耗药量,本实验探讨微型高通量技术筛选药物纳米晶体稳定剂的可行性与优点。方法使用自行研发的微型高通量纳米制备创新技术,对美洛昔康、吲哚美辛、克霉唑、格列本脲的最适稳定剂进行筛选,以平均粒径、物理稳定性等为标准进行分析。结果经实验发现,微型高通量纳米制备技术筛选药物纳米晶体稳定剂,与常规实验方法相比,不仅减少了耗药量,而且缩短了筛选时间。结论此方法与扩大规模后的制备有可比的结果,具有较好的应用前景。
OBJECTIVE To shorten preparation time of drug nanocrystals and reduce drug consumption. METHODS In this experiment, the optimal stabilizers of meloxicam, indomethacin, clotrimazole and glibenclamide were screened by miniature high-throughput technology, and the average particle size and physical stability were analyzed to explore the feasibility and advantages of miniature high-throughput technology in screening drug nanocrystals′ stabilizers.RESULTS It is found that the screening of drug nanocrystal stabilizers by miniature high-throughput technology reduces the drug consumption and shortens the screening time compared with conventional experimental methods. CONCLUSION It has comparable results with the scale-up preparation, which has good application.
作者
陈嘉冬
秦治国
田海云
刘涛
CHEN Jia-dong;QIN Zhi-guo;TIAN Hai-yun;LIU Tao(College of Chemical Engineering,Qingdao University of Science and Technology,Qingdao 266042,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2021年第18期1503-1507,共5页
Chinese Pharmaceutical Journal
基金
山东省高等学校科学技术计划项目资助(J18KA269)
山东省重点研发计划资助(2019GSF107006)
青岛市源头创新计划资助(19-6-2-38-cg)。
关键词
纳米晶体
稳定剂
微型高通量
可行性
nanocrystal
stabilizer
miniature high-throughput
feasibility
